United States Needle Free Injections Market Outlook to 2023

United States Needle Free Injections Market Outlook to 2023


  • Products Id :- GDMECC2507DB
  • |
  • Pages: 82
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

United States Needle Free Injections Market Outlook to 2023

Summary

GlobalData's new report, "United States Needle Free Injections Market Outlook to 2023", provides key market data on the United States Needle Free Injections market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for Needle Free Injections.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

Market size and company share data for Needle Free Injections.

Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.

2016 company shares and distribution shares data for each of the market segments.

Global corporate-level profiles of key companies operating within the United States Needle Free Injections market.

Key players covered include INJEX-Equidyne Systems, Bioject Medical Technologies Inc and Antares Pharma Inc.

Reasons to buy

Develop business strategies by identifying the key market segments poised for strong growth in the future.

Develop market-entry and market expansion strategies.

Design competition strategies by identifying who-stands-where in the market.

Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 5

2 Introduction 6

2.1 What Is This Report About? 6

2.2 Needle Free Injections Market Segmentation 6

2.3 Definitions of Markets Covered in the Report 7

3 Needle Free Injections Market, United States 8

3.1 Needle Free Injections Market, United States, Revenue ($m), 2009-2016 8

3.2 Needle Free Injections Market, United States, Revenue ($m), 2016-2023 9

3.3 Needle Free Injections Market, United States, Volume (Units), 2009-2016 10

3.4 Needle Free Injections Market, United States, Volume (Units), 2016-2023 11

3.5 Needle Free Injections Market, United States, Average Price ($), 2009-2023 12

3.6 Needle Free Injections Market, United States, Distribution Share by Revenue ($m), 2015-2016 13

3.7 Needle Free Injections Market, United States, Company Share by Revenue ($m), 2016 14

4 Overview of Key Companies in United States, Needle Free Injections Market 16

4.1 INJEX-Equidyne Systems 16

4.1.1 Company Overview 16

4.2 Bioject Medical Technologies Inc 16

4.2.1 Company Overview 16

4.3 Antares Pharma Inc 16

4.3.1 Company Overview 16

4.4 PharmaJet Inc 16

4.4.1 Company Overview 16

4.5 MK Global Co. 16

4.5.1 Company Overview 16

5 Needle Free Injections Market Pipeline Products 17

6 Financial Deals Landscape 18

6.1 Debt Offerings 18

6.1.1 Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 18

6.1.2 Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 20

6.2 Equity Offerings 22

6.2.1 Valeritas Files Registration Statement for IPO for up to USD50 Million 22

6.3 Partnerships 24

6.3.1 PharmaJet Enters into Agreement with Serum Institute of India 24

6.4 Venture Financing 25

6.4.1 Pharmajet Raises USD3 Million in Venture Financing 25

6.4.2 Enable Injections Raises USD30 Million in Series A Financing 26

6.4.3 QuiO Technologies Raises USD1.05 Million in Seed Financing 28

6.4.4 Enable Injections Raises USD10 Million in Venture Financing 29

7 Recent Developments 30

7.1 Corporate Communications 30

7.1.1 Jun 06, 2017: Valeritas Appoints Peter J. Devlin to Chairman of its Board of Directors 30

7.1.2 Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 30

7.1.3 Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency 30

7.1.4 Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board 31

7.1.5 Jan 05, 2017: Zogenix Announces CFO Transition 31

7.1.6 Nov 30, 2016: Valeritas Elects Joe Mandato, Ph.D., Experienced Medical Device Executive and Investor, to Board of Directors 32

7.1.7 Nov 17, 2016: OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology 33

7.1.8 Nov 15, 2016: Oncoceutics Presents Abstracts on ONC201 at 2016 American Society of Hematology Meeting 34

7.1.9 Nov 14, 2016: Olympus VISERA 4K UHD Receives "Excellence in Surgical Products Awards," Minimally Invasive Surgical Product Category 35

7.1.10 Oct 31, 2016: Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer 35

7.1.11 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 36

7.1.12 Sep 22, 2016: Industry Veteran Katherine D. Crothall, PhD to Join Valeritas Board of Directors 37

7.1.13 Aug 16, 2016: Valeritas Appoints Erick J. Lucera as Chief Financial Officer 37

7.1.14 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors 38

7.1.15 Jul 13, 2016: Valeritas Appoints Brian K. Roberts to its Board of Directors 38

7.2 Financial Announcements 39

7.2.1 May 15, 2017: Aradigm Announces First Quarter 2017 Financial Results 39

7.2.2 May 12, 2017: Valeritas Reports First Quarter 2017 Financial Results 39

7.2.3 May 10, 2017: ICU Medical Announces First Quarter 2017 Results 40

7.2.4 May 09, 2017: Antares Pharma Reports First Quarter 2017 Operating and Financial Results 40

7.2.5 May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results 42

7.2.6 May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 42

7.2.7 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 43

7.2.8 Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017 44

7.2.9 Mar 28, 2017: Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results 46

7.2.10 Mar 14, 2017: Antares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results 47

7.2.11 Mar 09, 2017: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 48

7.2.12 Mar 01, 2017: ICU Medical Announces Fourth Quarter and Fiscal Year 2016 Results 49

7.2.13 Feb 21, 2017: Valeritas Reports Fourth Quarter and Full Year 2016 Financial Results 50

7.2.14 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 51

7.2.15 Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 52

7.2.16 Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results 53

7.2.17 Nov 10, 2016: Valeritas Reports Third Quarter 2016 Financial Results 55

7.2.18 Nov 09, 2016: Antares Pharma Reports Third Quarter 2016 Financial and Operating Results 56

7.2.19 Nov 09, 2016: Aradigm Announces Third Quarter 2016 Financial Results 57

7.2.20 Nov 09, 2016: ICU Medical Announces Third Quarter 2016 Results 58

7.2.21 Nov 08, 2016: Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results 59

7.2.22 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 60

7.2.23 Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016 61

7.2.24 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 62

7.2.25 Aug 10, 2016: Aradigm Announces Second Quarter 2016 Financial Results 65

7.2.26 Aug 10, 2016: Valeritas Reports Second Quarter 2016 Financial Results 66

7.2.27 Aug 09, 2016: Antares Pharma Reports Second Quarter 2016 Operating and Financial Results 66

7.2.28 Aug 09, 2016: Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results 68

7.2.29 Aug 08, 2016: ICU Medical Announces Second Quarter 2016 Results 69

7.2.30 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 69

7.2.31 Jul 26, 2016: Baxter Reports Second Quarter 2016 Results and Raises Financial Outlook for Full-Year 2016 71

7.3 Government and Public Interest 72

7.3.1 Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 72

7.3.2 Sep 27, 2016: Orange County Business Council Study Showcases Economic Impact of Allergan on California Economy 72

7.4 Legal And Regulatory 73

7.4.1 Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges 73

7.4.2 Nov 17, 2016: New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating Soliris (eculizumab) Treatment Prior to Transplant Compared to Initiating Treatment Post-Transplant 73

7.5 Other Significant Developments 75

7.5.1 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 75

7.5.2 Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration 77

7.5.3 Jul 15, 2016: PhRMA Welcomes Five New Member Companies 77

8 Appendix 78

8.1 Research Methodology 79

8.1.1 Coverage 79

8.1.2 Secondary Research 79

8.1.3 Primary Research 80

8.1.4 Company Share Analysis 80

8.1.5 Distribution Share Analysis 80

8.1.6 Benchmarking 81

8.2 GlobalData Consulting 81

8.3 Contact Us 82

8.4 Disclaimer 82

1.2 List of Figures

Figure 1: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 8

Figure 2: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 9

Figure 3: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 10

Figure 4: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 11

Figure 5: Needle Free Injections Market, United States, Company Share (%) 2016 14

1.1 List of Tables

Table 1: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 8

Table 2: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 9

Table 3: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 10

Table 4: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 11

Table 5: Needle Free Injections Market, United States, Average Price ($), Historic, 2009-2016 12

Table 6: Needle Free Injections Market, United States, Average Price ($), Forecast, 2016-2023 12

Table 7: Needle Free Injections Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 13

Table 8: Needle Free Injections Market, United States, Company Share by Revenue ($m), USD Constant, 2016 15

Table 9: Needle Free Injections Market Pipeline Products 17

Table 10: Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 18

Table 11: Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 20

Table 12: Valeritas Files Registration Statement for IPO for up to USD50 Million 22

Table 13: PharmaJet Enters into Agreement with Serum Institute of India 24

Table 14: Pharmajet Raises USD3 Million in Venture Financing 25

Table 15: Enable Injections Raises USD30 Million in Series A Financing 26

Table 16: QuiO Technologies Raises USD1.05 Million in Seed Financing 28

Table 17: Enable Injections Raises USD10 Million in Venture Financing 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

INJEX-Equidyne Systems

Bioject Medical Technologies Inc

Antares Pharma Inc

PharmaJet Inc

MK Global Co.

Drug Delivery Devices, Central Venous Catheters, Needle Free Injections, Infusion Systems, Metered Dose Inhaler Devices, Value (USD), Volume (units), Revenues, Historic Revenues, Forecast Revenues, Average Price, Company Share, Distribution Share by Revenue, Company Share by Revenue, Pipeline Products, News, Deals, Key Companies, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Pfizer Inc, Merck & Co Inc, Sunovion Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, INJEX-Equidyne Systems, Bioject Medical Technologies Inc , Antares Pharma Inc, PharmaJet Inc, MK Global Co., The European Pharma Group, Hospira Inc, Becton Dickinson and Co, Baxter International Inc, Fresenius Kabi AG, Medtronic plc, B. Braun Melsungen AG, Terumo Corp, Smiths Medical, Nipro Corp, JMS Co Ltd

select a license

Single User License
USD 4995 INR 323476
Site License
USD 9990 INR 646952
Corporate User License
USD 14985 INR 970429

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com